{"transactions":[{"id":910034,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Option (right to buy)","published_at":"2026-02-12T02:01:51.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the \"Vesting Commencement Date\") and thereafter, an additional one fortyeighth\n(1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable\nwith respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":23.71,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001771329-26-000001","document":"form4-02122026_020247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000177132926000001/form4-02122026_020247.xml","form_type":"4"}},{"id":1115086,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Option (right to buy)","published_at":"2025-06-11T21:47:11.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":12.47,"expiration_date":"2035-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-25-016729","document":"form4-06112025_090608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925016729/form4-06112025_090608.xml","form_type":"4"}},{"id":1546792,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO GENERAL COUNSEL SECRETARY"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:09.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":215000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":6.78,"expiration_date":"2033-02-10","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001415889-24-010424","document":"form4-04052024_040402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010424/form4-04052024_040402.xml","form_type":"4"}},{"id":1546791,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO GENERAL COUNSEL SECRETARY"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:09.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":135000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":10.03,"expiration_date":"2032-02-11","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001415889-24-010424","document":"form4-04052024_040402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010424/form4-04052024_040402.xml","form_type":"4"}},{"id":1546790,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO GENERAL COUNSEL SECRETARY"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:09.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":35.38,"expiration_date":"2031-02-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-24-010424","document":"form4-04052024_040402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010424/form4-04052024_040402.xml","form_type":"4"}},{"id":1546789,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO GENERAL COUNSEL SECRETARY"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:09.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":121503,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":5.63,"expiration_date":"2030-08-18","underlying":"Common Stock","underlying_shares":121503},"source":{"system":"sec-edgar","filing":"0001415889-24-010424","document":"form4-04052024_040402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010424/form4-04052024_040402.xml","form_type":"4"}},{"id":1546788,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO GENERAL COUNSEL SECRETARY"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:09.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":384508,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option."}],"balance_after":0,"derivative":{"exercise_price":2.57,"expiration_date":"2030-04-02","underlying":"Common Stock","underlying_shares":384508},"source":{"system":"sec-edgar","filing":"0001415889-24-010424","document":"form4-04052024_040402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010424/form4-04052024_040402.xml","form_type":"4"}},{"id":1546787,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO GENERAL COUNSEL SECRETARY"}}],"security":"Common Stock","published_at":"2024-04-05T16:55:09.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27578,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 15,625 shares represented by restricted stock units (\"RSUs\"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-010424","document":"form4-04052024_040402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010424/form4-04052024_040402.xml","form_type":"4"}},{"id":1596855,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO GENERAL COUNSEL SECRETARY"}}],"security":"Common Stock","published_at":"2024-03-05T17:00:24.000Z","date":"2024-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":558,"price":2.59,"value":1445.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of restricted stock units (\"RSUs\") granted to the Reporting Person by the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 15,625 shares represented by restricted stock units (\"RSUs\"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date."}],"balance_after":27578,"source":{"system":"sec-edgar","filing":"0001415889-24-006753","document":"form4-03052024_050301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924006753/form4-03052024_050301.xml","form_type":"4"}},{"id":1721911,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO General Counsel Secretary"}}],"security":"Common Stock","published_at":"2023-12-05T17:00:14.000Z","date":"2023-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":541,"price":2.25,"value":1217.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of restricted stock units (\"RSUs\") granted to the Reporting Person by the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 17,188 shares represented by restricted stock units (\"RSUs\").  Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.  A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date."}],"balance_after":28136,"source":{"system":"sec-edgar","filing":"0001209191-23-057454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919123057454/doc4.xml","form_type":"4"}},{"id":1787327,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO General Counsel Secretary"}}],"security":"Common Stock","published_at":"2023-09-06T17:00:21.000Z","date":"2023-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":541,"price":2.35,"value":1271.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 18,750 shares represented by restricted stock units (\"RSUs\").  Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.  A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date."}],"balance_after":28677,"source":{"system":"sec-edgar","filing":"0001209191-23-048426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919123048426/doc4.xml","form_type":"4"}},{"id":1867271,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO General Counsel Secretary"}}],"security":"Common Stock","published_at":"2023-06-05T17:00:45.000Z","date":"2023-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":541,"price":4.3,"value":2326.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,313 shares represented by restricted stock units (\"RSUs\").  Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.  A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,473 shares acquired under the Issuers Employee Stock Purchase Plan in May 2023."}],"balance_after":29218,"source":{"system":"sec-edgar","filing":"0001209191-23-034444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919123034444/doc4.xml","form_type":"4"}},{"id":1974110,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO General Counsel Secretary"}}],"security":"Common Stock","published_at":"2023-03-03T17:57:39.000Z","date":"2023-03-01","kind":"tax_withholding","acquired":false,"shares":638,"price":5.21,"value":3323.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 21,875 shares represented by restricted stock units (\"RSUs\").  Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.  A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date."}],"balance_after":27286,"source":{"system":"sec-edgar","filing":"0001209191-23-015873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919123015873/doc4.xml","form_type":"4"}},{"id":2016664,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO General Counsel Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-14T17:00:56.000Z","date":"2023-02-10","kind":"grant","acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the \"Vesting Commencement Date\") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":215000,"derivative":{"exercise_price":6.78,"expiration_date":"2033-02-10","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001209191-23-009206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919123009206/doc4.xml","form_type":"4"}},{"id":2098448,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO General Counsel Secretary"}}],"security":"Common Stock","published_at":"2022-12-02T20:00:11.000Z","date":"2022-12-01","kind":"tax_withholding","acquired":false,"shares":541,"price":7.75,"value":4192.75,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 23,438 shares represented by restricted stock units (\"RSUs\").  Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.  A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date."}],"balance_after":27924,"source":{"system":"sec-edgar","filing":"0001209191-22-059513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919122059513/doc4.xml","form_type":"4"}},{"id":2167686,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO General Counsel Secretary"}}],"security":"Common Stock","published_at":"2022-09-02T17:00:15.000Z","date":"2022-09-01","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer granted RSUs to the Reporting Person. Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,729 shares acquired under the Issuer's Employee Stock Purchase Plan (the \"Plan\") in May 2021, 595 shares acquired under the Plan in November 2021, and  1,141 shares acquired under the Plan in May 2022."}],"balance_after":28465,"source":{"system":"sec-edgar","filing":"0001209191-22-048525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919122048525/doc4.xml","form_type":"4"}},{"id":2394676,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO General Counsel Treasurer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-15T16:01:05.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2022 (the \"Vesting Commencement Date\") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2026, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":135000,"derivative":{"exercise_price":10.03,"expiration_date":"2032-02-11","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001209191-22-009742","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919122009742/doc4.xml","form_type":"4"}},{"id":2859439,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO General Counsel Treasurer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-16T18:00:17.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option vests and becomes exercisable over time at the following rate: 1/48th of the total number of shares subject to the Option shall vest each month in equal installments starting on March 1, 2021."}],"balance_after":100000,"derivative":{"exercise_price":35.38,"expiration_date":"2031-02-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-21-010902","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919121010902/doc4.xml","form_type":"4"}},{"id":3310830,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:32:23.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":104000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":37.26,"expiration_date":"2029-03-28","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001209191-20-003431","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003431/doc4.xml","form_type":"4"}},{"id":3310829,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-01-15T13:32:23.000Z","date":"2020-01-15","kind":"other","acquired":false,"shares":32705,"price":60,"value":1962300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 28,000 shares of Company common stock issuable upon the settlement of restricted stock units."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-003431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003431/doc4.xml","form_type":"4"}},{"id":3340977,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2019-12-16T18:04:06.000Z","date":"2019-12-12","kind":"tax_withholding","acquired":false,"shares":4628,"price":59.37,"value":274764.36,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On December 10, 2019, the Compensation Committee of the Issuer's Board of Directors approved the accelerated vesting and settlement of restricted stock units granted on March 28, 2019 in order to mitigate the potential adverse tax consequences of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes."}],"balance_after":32705,"source":{"system":"sec-edgar","filing":"0001209191-19-060729","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119060729/doc4.xml","form_type":"4"}},{"id":3572020,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2019-04-01T17:54:29.000Z","date":"2019-03-28","kind":"grant","acquired":true,"shares":104000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest as to 25% of the total shares on March 28, 2020, and then 2.0833% of the shares monthly thereafter, such that the option is fully vested on March 28, 2023, subject to the Reporting Person's provision of service to the issuer on each vesting date."}],"balance_after":104000,"derivative":{"exercise_price":37.26,"expiration_date":"2029-03-28","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001209191-19-022056","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119022056/doc4.xml","form_type":"4"}},{"id":3572019,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2019-04-01T17:54:29.000Z","date":"2019-03-28","kind":"grant","acquired":true,"shares":37333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 25% of the award on March 5, 2020, and then 6.25% of the RSUs will vest quarterly on June 5, September 5, December 5, and March 5 such that the RSUs are fully vested on March 5, 2023, subject to the Reporting Person's provision of services to the issuer on each vesting date. Shares of the issuer's Common Stock will be delivered to the Reporting Person following vesting."}],"balance_after":37333,"source":{"system":"sec-edgar","filing":"0001209191-19-022056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119022056/doc4.xml","form_type":"4"}}]}